Lili Wang#, Xin Wang#, Hongyan Zhao*
Department of Critical Care, Daqing Oilfield General Hospital, Daqing 163001, Heilongjiang Province, China
Thymosin α1 is a small molecule polypeptide with immunomodulatory effect. When used in the treatment of severe pneumonia, it can improve the therapeutic effect, shorten the hospital stay, and improve the prognosis. Severe pneumonia usually manifests as severe hypoxemia and dyspnoea and can even involve other vital organs. Infectivity is one of the most important pathogenic factors for severe pneumonia. In addition to infectious factors, immune disorders also play a notable role in the occurrence and development of severe pneumonia. Based on this, this article has launched a study on the influence of thymosin α1 on T cell expression and prognosis in patients with severe pneumonia. The theoretical foundation for the research of this article is laid through the collection of relevant medical materials. This article selects 146 patients with severe pneumonia admitted to the People’s Hospital of this city from September 2015 to August 2017 as the research object. The patients were randomly divided into group A and group B, with 73 cases in each group. Patients in group A received treatments such as monitoring vital signs, oxygen inhalation, regulating electrolyte disturbances, and nutritional input, and were treated with ceftazidime and norfloxacin; group B was treated with thymosin α1 on the basis of group A. In addition, this article compares the ratio of T helper 17 cells, the ratio of regulatory T cells, helper T cell 17/regulatory T cells ratio, CD3+ ratio, CD4+ ratio, CD8+ ratio, CD4+/CD8+ ratio, and prognosis. The results of the study showed that after treatment, the ratio of T helper 17 cells and the ratio of T helper 17 cells/regulatory T cells of the two groups of patients were lower than before treatment, and that group B was lower than that of group A. The cell ratio was higher than before treatment, and group B was higher than group A. The CD3+ ratio, CD4+ ratio, and CD4+/CD8+ ratio of the two groups of patients were higher than before treatment, and group B was higher than group A. The CD8+ ratio of group B was lower than before treatment and lower than that of group A. The above results suggest that the possible mechanism of thymosin α1 in the treatment of severe pneumonia is to regulate the expression of T helper 17 cells and regulatory T cells, and then up-regulate the ratio of CD3+ and CD4+. In summary, thymosin α1 can regulate the expression of T cells in patients with severe pneumonia and reduce the risk of adverse reactions.
Thymosin α1, severe pneumonia, T Cell expression, cellular immunity.